PT93057A - Processo para a preparacao de analogos da insulina - Google Patents

Processo para a preparacao de analogos da insulina

Info

Publication number
PT93057A
PT93057A PT93057A PT9305790A PT93057A PT 93057 A PT93057 A PT 93057A PT 93057 A PT93057 A PT 93057A PT 9305790 A PT9305790 A PT 9305790A PT 93057 A PT93057 A PT 93057A
Authority
PT
Portugal
Prior art keywords
absent
lys
threonine
arg
aspartic acid
Prior art date
Application number
PT93057A
Other languages
English (en)
Other versions
PT93057B (pt
Inventor
Richard Dennis Dimarchi
Ronald Eugene Chance
Bruce Hill Frank
James Edwin Shields
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26976211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT93057(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PT93057A publication Critical patent/PT93057A/pt
Publication of PT93057B publication Critical patent/PT93057B/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C07K14/622—Insulins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT93057A 1989-02-09 1990-02-05 Processo para a preparacao de analogos da insulina PT93057B (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30835289A 1989-02-09 1989-02-09
US38820189A 1989-08-04 1989-08-04

Publications (2)

Publication Number Publication Date
PT93057A true PT93057A (pt) 1990-08-31
PT93057B PT93057B (pt) 1995-12-29

Family

ID=26976211

Family Applications (1)

Application Number Title Priority Date Filing Date
PT93057A PT93057B (pt) 1989-02-09 1990-02-05 Processo para a preparacao de analogos da insulina

Country Status (24)

Country Link
EP (2) EP0383472B1 (pt)
JP (1) JPH0822878B2 (pt)
KR (1) KR0169727B1 (pt)
CN (2) CN1034080C (pt)
AT (1) ATE133961T1 (pt)
AU (1) AU630912B2 (pt)
BG (1) BG60769B2 (pt)
CA (1) CA2009579C (pt)
CY (1) CY1911A (pt)
DE (3) DE19675034I2 (pt)
DK (2) DK0383472T3 (pt)
ES (2) ES2170122T3 (pt)
FI (1) FI95915C (pt)
GR (1) GR3019501T3 (pt)
HK (1) HK60296A (pt)
HU (2) HU212679B (pt)
IE (1) IE73251B1 (pt)
IL (1) IL93282A (pt)
LU (2) LU88831I2 (pt)
NL (1) NL960026I2 (pt)
NO (2) NO179587C (pt)
NZ (1) NZ232375A (pt)
PT (1) PT93057B (pt)
RU (1) RU2109749C1 (pt)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT56857A (en) * 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
US5716927A (en) * 1988-12-23 1998-02-10 Novo Nordisk A/S Insulin analogs having a modified B-chain
US5126249A (en) * 1989-05-09 1992-06-30 Eli Lilly And Company Enzymatic removal of a protein amino-terminal sequence
DK10191D0 (da) * 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
US5304473A (en) * 1991-06-11 1994-04-19 Eli Lilly And Company A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
TW222643B (pt) * 1991-06-21 1994-04-21 Lilly Co Eli
GB9316895D0 (en) 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
EP1607086A1 (en) * 1993-01-29 2005-12-21 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US6131567A (en) * 1993-01-29 2000-10-17 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5504188A (en) 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5559094A (en) * 1994-08-02 1996-09-24 Eli Lilly And Company AspB1 insulin analogs
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5597893A (en) 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5646242A (en) * 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
IL118127A0 (en) * 1995-05-05 1996-09-12 Lilly Co Eli Single chain insulin with high bioactivity
US5631347A (en) * 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
US5700904A (en) * 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
ATE208208T1 (de) * 1996-06-20 2001-11-15 Novo Nordisk As Halogenid-enthaltende insulinzubereitungen
EP0821006B1 (de) * 1996-07-26 2004-04-21 Aventis Pharma Deutschland GmbH Insulinderivate mit erhöhter Zinkbindung
SE520392C2 (sv) 1996-09-27 2003-07-01 Creative Peptides Sweden Ab C Specifika peptider för behandling av diabetes mellitus
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
IL134901A0 (en) 1997-10-24 2001-05-20 Lilly Co Eli Insoluble insulin compositions
CO4970787A1 (es) 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
US20010053761A1 (en) * 1998-01-08 2001-12-20 Dimarchi Richard Dennis Method for administering aspb28-human insulin
DE19805822B4 (de) * 1998-02-13 2009-02-05 Solvay Pharmaceuticals Gmbh 11-Acetyl-12,13-dioxabicyclo[8.2.1]tridecenon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
CN1125081C (zh) * 1999-09-08 2003-10-22 中国科学院上海生物化学研究所 重组天然和新型人胰岛素及其制备方法
US7638618B2 (en) 2001-02-20 2009-12-29 Sanofi-Aventis Deutschland Gmbh Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
US7202059B2 (en) 2001-02-20 2007-04-10 Sanofi-Aventis Deutschland Gmbh Fusion proteins capable of being secreted into a fermentation medium
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
EP1506003A1 (en) * 2002-05-07 2005-02-16 Novo Nordisk A/S Soluble formulations comprising insulin aspart and insulin detemir
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US7193035B2 (en) 2002-10-29 2007-03-20 Sanofi-Aventis Deutschland Gmbh Crystals of insulin analogs and processes for their preparation
RU2352581C2 (ru) 2003-08-05 2009-04-20 Ново Нордиск А/С Производные инсулина
WO2005012347A2 (en) 2003-08-05 2005-02-10 Novo Nordisk A/S Novel insulin derivatives
US20060287221A1 (en) 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
ATE525083T1 (de) * 2003-11-13 2011-10-15 Novo Nordisk As Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung
CN104826116A (zh) 2003-11-20 2015-08-12 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
EP1692168B1 (en) 2003-12-03 2011-07-20 Novo Nordisk A/S Single-chain insulin
UA91512C2 (ru) 2004-07-19 2010-08-10 Биокон Лимитед Коньюгати олигомеров инсулина, их композиция (варианты) и применение
ES2438145T3 (es) 2005-02-02 2014-01-16 Novo Nordisk A/S Nuevos derivados de insulina
US20080171695A1 (en) 2005-02-02 2008-07-17 Novo Nordisk A/S Insulin Derivatives
JPWO2006093222A1 (ja) * 2005-03-02 2008-08-07 味の素株式会社 インスリンの多量体形成阻害剤
US9056921B2 (en) 2005-08-16 2015-06-16 Novo Nordisk A/S Method for making mature insulin polypeptides
MX2008003362A (es) 2005-09-14 2008-03-25 Sanofi Aventis Deutschland Escision de precursores de insulinas mediante una variante de tripsina.
EP2505593A1 (en) 2005-12-28 2012-10-03 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
ES2387955T3 (es) 2006-02-27 2012-10-04 Novo Nordisk A/S Derivados de insulina
WO2007104786A1 (en) 2006-03-15 2007-09-20 Novo Nordisk A/S Mixtures of amylin and insulin
EP2024390B1 (en) 2006-05-09 2015-08-19 Novo Nordisk A/S Insulin derivative
ES2395738T3 (es) 2006-05-09 2013-02-14 Novo Nordisk A/S Derivado de insulina
BRPI0717098B8 (pt) 2006-09-22 2021-05-25 Novo Nordisk As análogos de insulina humana resistentes à protease, composição farmacêutica e processo para sua preparação
EP2502618A3 (en) 2007-04-30 2012-10-03 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
JP2011504871A (ja) 2007-06-01 2011-02-17 ノボ・ノルデイスク・エー／エス 固体又は半固体担体中にペプチド薬剤を含む自然に分散可能なプレコンセントレイト
CA2716159A1 (en) 2007-06-01 2008-12-04 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
CN101677947B (zh) 2007-06-13 2013-07-17 诺沃-诺迪斯克有限公司 包含胰岛素衍生物的药物制剂
PL2229407T3 (pl) 2008-01-09 2017-06-30 Sanofi-Aventis Deutschland Gmbh Nowe pochodne insuliny o ekstremalnie spowolnionym profilu czasu działania
DE102008051834A1 (de) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
KR101820024B1 (ko) 2008-10-17 2018-01-18 사노피-아벤티스 도이칠란트 게엠베하 인슐린과 ｇｌｐ－1 효능제의 병용물
DE102009038210A1 (de) 2009-08-20 2011-03-03 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
DE102008053048A1 (de) 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
SG10201403840VA (en) 2009-07-06 2014-10-30 Sanofi Aventis Deutschland Aqueous insulin preparations containing methionine
JP5675799B2 (ja) 2009-07-06 2015-02-25 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 遅効性インスリン製剤
WO2011003820A1 (de) * 2009-07-06 2011-01-13 Sanofi-Aventis Deutschland Gmbh Hitze- und schüttelstabile insulinzubereitungen
MX2012001141A (es) 2009-07-31 2012-03-29 Sanofi Aventis Deutschland Composicion de insulina de accion prolongada.
NZ598021A (en) 2009-07-31 2014-05-30 Sanofi Aventis Deutschland Prodrugs comprising an insulin linker conjugate
EP3345593B1 (de) 2009-11-13 2023-09-06 Sanofi-Aventis Deutschland GmbH Pharmazeutische zusammensetzung umfassend despro36exendin-4(1-39)-lys6-nh2 und methionin
TR201809460T4 (tr) 2009-11-13 2018-07-23 Sanofi Aventis Deutschland Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
BR112012028766A2 (pt) 2010-05-10 2017-06-13 Novo Nordisk As processo para a preparação de complexos de insulina e zinco
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
PL2632478T3 (pl) 2010-10-27 2020-03-31 Novo Nordisk A/S Leczenie cukrzycy z zastosowaniem zastrzyków insuliny podawanych w różnych odstępach czasu
JP6049625B2 (ja) 2010-10-27 2016-12-21 ノヴォ ノルディスク アー／エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
CN102199206B (zh) * 2011-03-17 2013-03-20 甘李药业股份有限公司 快速起效且在酸性条件下稳定的胰岛素类似物及其制剂
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
TWI608847B (zh) 2011-08-29 2017-12-21 賽諾菲阿凡提斯德意志有限公司 用於控制糖尿病二型病患血糖的醫藥組合物
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
RU2670106C2 (ru) 2012-05-01 2018-10-18 Ново Нордиск А/С Фармацевтическая композиция
WO2013173923A1 (en) 2012-05-25 2013-11-28 Diamedica, Inc. Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
WO2013181755A1 (en) 2012-06-04 2013-12-12 Diamedica Inc. Human tissue kallikrein 1 glycosylation isoforms
WO2014093696A2 (en) 2012-12-12 2014-06-19 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment
JP6111475B2 (ja) 2012-12-19 2017-04-12 ウォックハート リミテッド ヒトインスリン又はその類似体もしくは誘導体を含む安定な水性組成物
CN104870469A (zh) 2012-12-26 2015-08-26 沃克哈特有限公司 药物组合物
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
AR095986A1 (es) * 2013-04-03 2015-11-25 Sanofi Sa Proteínas modificadas que regulan glucosa en sangre con perfil alterado de actividad farmacológica y preparación de las mismas
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
US20160271226A1 (en) 2013-09-30 2016-09-22 Wockhardt Limited Pharmaceutical composition
WO2015104314A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
SG11201604708VA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
KR20160101195A (ko) 2014-01-09 2016-08-24 사노피 인슐린 아스파트의 안정화된 약제학적 제형
WO2015191705A1 (en) * 2014-06-10 2015-12-17 California Institute Of Technology Non-canonical insulins and their uses
WO2016001862A1 (en) 2014-07-04 2016-01-07 Wockhardt Limited Extended release formulations of insulins
PE20171622A1 (es) 2014-12-12 2017-11-02 Sanofi Aventis Deutschland Formulacion de relacion fija de insulina glargina/lixisenatida
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
CN110546161B (zh) * 2016-09-23 2024-01-26 韩美药品股份有限公司 对胰岛素受体具有降低的结合力的胰岛素类似物及其用途
JP2019529506A (ja) 2016-09-29 2019-10-17 アレコル リミテッド 新規の製剤
US11857608B2 (en) 2017-03-09 2024-01-02 Diamedica Inc. Dosage forms of tissue kallikrein 1
GB201707188D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707189D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707187D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
IL277731B2 (en) 2018-04-04 2024-03-01 Arecor Ltd A medical infusion pump system for administration of an insulin compound
WO2019193351A1 (en) 2018-04-04 2019-10-10 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
CN111989088A (zh) 2018-04-04 2020-11-24 艾瑞克有限公司 用于递送胰岛素化合物的医用输注泵系统
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
KR20200082618A (ko) 2018-12-31 2020-07-08 주식회사 폴루스 인슐린 과발현용 램프 태그 및 이를 이용한 인슐린의 제조방법
BR112022013042A2 (pt) 2019-12-30 2022-10-18 Gan & Lee Pharmaceuticals Co Ltd Composto da fórmula b, formulação farmacêutica, composição farmacêutica, método para tratar ou prevenir hiperglicemia, diabetes e/ou obesidade
WO2021136293A1 (zh) 2019-12-30 2021-07-08 甘李药业股份有限公司 胰岛素衍生物
GB202004814D0 (en) 2020-04-01 2020-05-13 Arecor Ltd Novel formulations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK129385A (da) * 1985-03-22 1986-09-23 Novo Industri As Peptider og fremstilling deraf
US5126249A (en) * 1989-05-09 1992-06-30 Eli Lilly And Company Enzymatic removal of a protein amino-terminal sequence

Also Published As

Publication number Publication date
ES2083424T3 (es) 1996-04-16
NO1996013I1 (no) 1996-12-09
LU88831I2 (fr) 1997-01-10
EP0383472A2 (en) 1990-08-22
ES2170122T3 (es) 2002-08-01
CN1103602C (zh) 2003-03-26
DK0383472T3 (da) 1996-05-06
CA2009579A1 (en) 1990-08-09
ATE133961T1 (de) 1996-02-15
HU211276A9 (en) 1995-11-28
NZ232375A (en) 1992-04-28
EP0678522A1 (en) 1995-10-25
NO179587C (no) 1996-11-06
FI95915C (fi) 1996-04-10
DE69033889D1 (de) 2002-02-07
NO900615L (no) 1990-08-10
DK0678522T3 (da) 2002-03-11
FI95915B (fi) 1995-12-29
PT93057B (pt) 1995-12-29
JPH0822878B2 (ja) 1996-03-06
JPH02264798A (ja) 1990-10-29
FI900600A0 (fi) 1990-02-07
HUT57795A (en) 1991-12-30
EP0383472A3 (en) 1991-09-18
IE900440L (en) 1990-08-09
CN1148984A (zh) 1997-05-07
HU212679B (en) 1996-09-30
BG60769B2 (bg) 1996-02-29
IL93282A0 (en) 1990-11-29
KR0169727B1 (ko) 1999-01-15
GR3019501T3 (en) 1996-07-31
AU630912B2 (en) 1992-11-12
DE69025210T2 (de) 1996-06-13
DE19675034I2 (de) 2006-11-16
CN1044820A (zh) 1990-08-22
CA2009579C (en) 2000-04-11
NL960026I2 (nl) 1997-05-01
EP0383472B1 (en) 1996-02-07
NO900615D0 (no) 1990-02-08
KR900012627A (ko) 1990-09-01
LU88830I2 (fr) 1997-01-06
DE69033889T2 (de) 2002-08-22
NL960026I1 (nl) 1997-01-06
AU4922690A (en) 1990-08-16
CY1911A (en) 1990-02-06
HK60296A (en) 1996-04-12
HU900726D0 (en) 1990-04-28
CN1034080C (zh) 1997-02-19
IE73251B1 (en) 1997-05-21
NO179587B (no) 1996-07-29
RU2109749C1 (ru) 1998-04-27
IL93282A (en) 1995-08-31
DE69025210D1 (de) 1996-03-21
EP0678522B1 (en) 2002-01-02

Similar Documents

Publication Publication Date Title
PT93057A (pt) Processo para a preparacao de analogos da insulina
HU906177D0 (en) Process for the production of peptide derivatives and medical and diagnostical preparations containing such derivatives
EP0512042A4 (en) Glp-1 analogs useful for diabetes treatment
WO2000012542A3 (en) Cytotoxic lactoferrin derivatives modified by bulky or lipophilic moieties
KR880001701A (ko) 신규한 펩티드
PT99565A (pt) Processo para a preparacao de factores de crescimento de fibroblastos quimerico s
ATE95195T1 (de) Mikroproteine, verfahren zur herstellung derselben und anwendung dieser mikroproteine als arzneimittel.
KR910002899A (ko) 혈조절 펩타이드
FI925972A (fi) Ny polypeptid med affinitet till lipopolysackarider och dess anvaendning
DE69302921D1 (de) Neue Peptidderivate, Verfahren zu deren Herstellung und deren Anwendung als Heilmittel
KR920012114A (ko) 사람 면역결핍 바이러스(HIV)의 그룹-특이 항원(gaa)의 선택된 펩타이드, 이의 제법 및 용도
ATE207496T1 (de) Neue peptide und nootroper wirkstoff
RU93004930A (ru) Днк, соматотропин, плазмиды, рекомбинантные организмы, композиция, способ получения соматотропина, способы стимулирования роста

Legal Events

Date Code Title Description
FG3A Patent granted, date of granting

Effective date: 19950929